SEC 13F Intelligence

Managers / Q4 2019 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$1.6B
Q4 2019
Positions
35
Filings on Record
15
2019–present window
Filed
Feb 14, 2020
original filing

Summary

Consonance Capital Management LP reported $1.6B in U.S.-listed holdings across 35 positions for Q4 2019.

Its largest position, AUPH, represents 8.2% of the portfolio.

Compared with Q3 2019, the fund opened 13 new positions and exited 8.

Portfolio Metrics

Turnover
+27.2%
vs prior filed quarter
Top-10 Concentration
+56.6%
share of reported value
Largest Position
+8.2%
Aurinia Pharmaceuticals
New / Exited
13 / 8
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 87.8%Other: 8.3%ADR: 3.9%
  • Common Stock · 87.8% · $1.4B
  • Other · 8.3% · $137M
  • ADR · 3.9% · $64M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GW PHARMACEUTICALS PLCNEW+604.6K604.6K+$63M$63M
EXKEXACT SCIENCES CORPNEW+579.7K579.7K+$54M$54M
AXGNAXOGEN INCNEW+2.99M2.99M+$53M$53M
ASSEMBLY BIOSCIENCES INCNEW+1.88M1.88M+$38M$38M
IVERIC BIO INCNEW+3.43M3.43M+$29M$29M
LIMINAL BIOSCIENCES INCNEW+3.29M3.29M+$28M$28M
APTOSE BIOSCIENCES INCNEW+4.77M4.77M+$27M$27M
OVIDOVID THERAPEUTICS INCNEW+2.89M2.89M+$12M$12M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

35 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AUPHAURINIA PHARMACEUTICALS INChistory →COM8.19%$134M6.63M
2ARQULE INCCOM8.18%$134M6.72M
3KARYOPHARM THERAPEUTICS INCCOM7.17%$117M6.13M
4EPIZYME INCCOM6.47%$106M4.31M
5UTHRUNITED THERAPEUTICS CORP DELhistory →COM4.94%$81M919.3K
6CHEMOCENTRYX INCCOM4.59%$75M1.90M
7ALGNALIGN TECHNOLOGY INChistory →COM4.58%$75M269.0K
8KDMNKADMON HLDGS INChistory →COM4.32%$71M15.64M
9INTRA CELLULAR THERAPIES INCCOM4.14%$68M1.98M
10QUREUNIQURE NVhistory →SHS4.06%$67M929.0K
11GW PHARMACEUTICALS PLCADS3.86%$63M604.6K
12EXKEXACT SCIENCES CORPhistory →COM3.27%$54M579.7K
13AXGNAXOGEN INChistory →COM3.26%$53M2.99M
14SRPTSAREPTA THERAPEUTICS INChistory →COM2.80%$46M356.1K
15CDNACAREDX INChistory →COM2.79%$46M2.12M
16OMEROMEROS CORPhistory →COM2.75%$45M3.20M
17IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM2.55%$42M1.51M
18OXFORD IMMUNOTEC GLOBAL PLCORD SHS2.39%$39M2.36M
19ASSEMBLY BIOSCIENCES INCCOM2.35%$38M1.88M
20RETROPHIN INCCOM2.01%$33M2.31M
21TNDMTANDEM DIABETES CARE INChistory →COM NEW2.00%$33M551.0K
22IVERIC BIO INCCOM1.79%$29M3.43M
23LIMINAL BIOSCIENCES INCCOM1.68%$28M3.29M
24VCELVERICEL CORPhistory →COM1.65%$27M1.56M
25APTOSE BIOSCIENCES INCCOM NEW1.65%$27M4.77M
26PODDINSULET CORPhistory →COM1.63%$27M155.8K
27ADMAADMA BIOLOGICS INChistory →COM1.26%$21M5.17M
28STAASTAAR SURGICAL COhistory →COM PAR $0.010.91%$15M425.8K
29OVIDOVID THERAPEUTICS INChistory →COM0.73%$12M2.89M
30KRYSKRYSTAL BIOTECH INChistory →COM0.69%$11M203.8K
31BIOTELEMETRY INCCOM0.44%$7M155.0K
32AMICUS THERAPEUTICS INCCOM0.30%$5M507.7K
33TURNING POINT THERAPEUTICS ICOM0.27%$4M71.3K
34APELLIS PHARMACEUTICALS INCCOM0.25%$4M135.0K
35MORPHOSYS AGSPONSORED ADS0.05%$769,00021.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.